ENHANCED RESTORATION OF STRIATAL DOPAMINE CONCENTRATIONS BY COMBINED GM1 GANGLIOSIDE AND NEUROTROPHIC FACTOR TREATMENTS

被引:16
|
作者
SCHNEIDER, JS
DISTEFANO, L
机构
关键词
1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; DOPAMINE; MOUSE; GM1; GANGLIOSIDE; FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR;
D O I
10.1016/0006-8993(94)01450-V
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Intraperitoneal injection of GM1 ganglioside or intracerebroventricular infusion of basic fibroblast growth factor (FGF-2) or epidermal growth factor (EGF) partially restored dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the striatum of young MPTP-treated mice. Combined treatments of GM1 ganglioside with FGF-2 or EGF produced a greater restoration of striatal dopamine levels than treatments with GM1 or either of the neurotrophic factors alone. GM1 treatment, but not trophic factor treatments, caused significant sparing of substantia nigra pars compacta (SNc) tyrosine hydroxylase (TH)-positive neurons. These results confirm previous findings that GM1 provides trophic support for damaged dopamine neurons and suggests that GM1, FGF-2, and EGF may also enhance dopaminergic function in residual neurons. The results also suggest that a potentially fruitful approach to treating degenerative disorders of the dopamine system may be the use of combined trophic factor therapies.
引用
收藏
页码:260 / 264
页数:5
相关论文
共 50 条
  • [31] EFFECTS OF EXOGENOUS GM1 GANGLIOSIDE ON LTP IN RAT HIPPOCAMPAL SLICES PERFUSED WITH DIFFERENT CONCENTRATIONS OF CALCIUM
    HWANG, HM
    WANG, JT
    CHIU, TH
    NEUROSCIENCE LETTERS, 1992, 141 (02) : 227 - 230
  • [32] Bis(monoacylglycero)phosphate and ganglioside GM1 spontaneously form small homogeneous vesicles at specific concentrations
    Chebukati, Janetricks N.
    Goff, Philip C.
    Frederick, Thomas E.
    Fanucci, Gail E.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (03) : 509 - 514
  • [33] Effects of ganglioside GM1 and neural growth factor on neural stem cell proliferation and differentiation
    Wang, Q.
    Song, Y. H.
    Tang, Z.
    Wang, Z. P.
    Xu, Q.
    Bao, N.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (03):
  • [34] GM1 ganglioside activates the high affinity nerve growth factor receptor trkA.
    Rabin, SJ
    Mocchetti, J
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S40 - S40
  • [35] GANGLIOSIDE GM1 COOPERATES WITH BRAIN-DERIVED NEUROTROPHIC FACTOR TO PROTECT DOPAMINERGIC-NEURONS FROM 6-HYDROXYDOPAMINE-INDUCED DEGENERATION
    FADDA, E
    NEGRO, A
    FACCI, L
    SKAPER, SD
    NEUROSCIENCE LETTERS, 1993, 159 (1-2) : 147 - 150
  • [36] EFFECT OF GM1 GANGLIOSIDE TREATMENT ON THE RECOVERY OF DOPAMINERGIC NIGRO-STRIATAL NEURONS AFTER DIFFERENT TYPES OF LESION
    TOFFANO, G
    AGNATI, LF
    FUXE, K
    ALDINIO, C
    CONSOLAZIONE, A
    VALENTI, G
    SAVOINI, G
    ACTA PHYSIOLOGICA SCANDINAVICA, 1984, 122 (03): : 313 - 321
  • [37] Neurotrophic effects of GM1 ganglioside, NGF, and FGF2 on canine dorsal root ganglia neurons in vitro
    S. Schwarz
    A. Lehmbecker
    W. Tongtako
    K. Hahn
    Y. Wang
    F. Felmy
    I. Zdora
    G. Brogden
    K. Branitzki-Heinemann
    M. von Köckritz-Blickwede
    W. Baumgärtner
    I. Gerhauser
    Scientific Reports, 10
  • [38] Neurotrophic effects of GM1 ganglioside, NGF, and FGF2 on canine dorsal root ganglia neurons in vitro
    Schwarz, S.
    Lehmbecker, A.
    Tongtako, W.
    Hahn, K.
    Wang, Y.
    Felmy, F.
    Zdora, I
    Brogden, G.
    Branitzki-Heinemann, K.
    Von Koeckritz-Blickwede, M.
    Baumgaertner, W.
    Gerhauser, I
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] GM1 GANGLIOSIDE TREATMENT PROMOTES RECOVERY OF ELECTRICALLY-STIMULATED [3H]DOPAMINE RELEASE IN STRIATAL SLICES FROM RATS LESIONED WITH KAINIC ACID
    RAITERI, M
    BONANNO, G
    PENDE, M
    VERSACE, P
    NEUROSCIENCE LETTERS, 1992, 136 (01) : 127 - 130
  • [40] TREATMENT WITH GM1 GANGLIOSIDE REVERSES DOPAMINE D-2-RECEPTOR SUPERSENSITIVITY INDUCED BY THE NEUROTOXIN MPTP
    HADJICONSTANTINOU, M
    WEIHMULLER, F
    NEFF, NH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 168 (02) : 261 - 264